KWMG
VYNE icon

King Wealth Management Group’s VYNE Therapeutics VYNE Stock Holding History

King Wealth Management Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-159
Closed -$19K – 167
2020
Q3 		$19K Hold
159
– – ﹤0.01% 158
2020
Q2 		$20K Buy
+159
New +$21.5K 0.01% 152

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

King Wealth Management Group's VYNE Position: Q4 2020 in Review

King Wealth Management Group sold out of VYNE Therapeutics (VYNE) in Q4 2020, closing a stake of 159 shares — an estimated $19K sold.

King Wealth Management Group first reported a position in VYNE in Q2 2020 and held it in 2 quarters. The position peaked at $20K in Q2 2020. 104 funds tracked by Wall St. Rank hold VYNE as of Q4 2020.

  • King Wealth Management Group reported no remaining VYNE Therapeutics position as of Q4 2020 after selling out during the quarter.
  • King Wealth Management Group sold 159 VYNE Therapeutics shares in Q4 2020, an estimated $19K.
  • King Wealth Management Group first reported a position in VYNE Therapeutics in Q2 2020 and held it in 2 quarters.
  • King Wealth Management Group's VYNE Therapeutics position peaked at $20K in Q2 2020.
  • 104 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2020.

Based on King Wealth Management Group's 13F filing for Q4 2020, filed 12 Feb 2021.